Monday, May 3, 2021

Amid weak showing by biosimilars and generics, downgrade pressure on Biocon

Analysts expect ramp-up in biosimilars to be gradual

from Today's Paper https://ift.tt/3eMoGs7
via
By at
Labels: ,

No comments:

Post a Comment

If you have any doubts please let me know!

Subscribe to: Post Comments (Atom)

India's low score on GVC a starting point for recovery from pandemic: AIIB

India rated 7.4 percentage points below the average global value chain participation rate for emerging economies from Today's Paper ht...